Search
Press Release: News on Red Cells and Iron presented at the 18th Congress of the European Hematology Asscociation in Stockholm June 13-16, 2013
Recent evidence suggests that these congenital anaemias are caused by molecular abnormalities in the transport of iron and other molecules and a deeper understanding of these mechanisms may lead to a better knowledge of the normal development of the red…
Read moreIVDR resources
IVD Taskforce Videos:Konstanze Döhner
\
Monika Brüggemann
IVDR Sessions:
HemaSphere articles:
Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
EU-Wide Access to…
Revising the ICH Guidelines on Clinical Trials
The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.
Read moreInfections in Hematology
The SWG on Infection in Hematology was founded in 2017 and follows four main goals:
Develop and share clinically useful tools: Many hematologists create checklists and pathways for quick and easy reference.
Publications
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld…
Nikolai Klimko 1956-2023
Professor Nikolai Klimko
Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023
With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
Meeting Program
Program by dayPlease click on the image to open the full program by day. Program-at-a-glance
Please click on the image to open the program-at-a-glance.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- »